Genetic Testing for BRCA1/2 Targeted-drug Guidance [ Germline + Somatic]

This germline testing detects somatic and germline SNV, InDel and CNV mutations in the BRCA1 and BRCA2 genes, covering the entire coding region of the BRCA1/2 gene and both flanking intron regions, provide information to guide PARP inhibitor therapy in breast & ovarian cancer.

Applicable Population of Targeted Medication Guidance for BRCA1/2
Cancer patients in need of PARP inhibitors.

Cancer patients requiring BRCA1/2 gene testing.

For more information about germline mutation analysis and in vitro diagnostics, please feel free to contact us!

There are many rna sequencing companies, but we are one of the best choices for you.

CapitalBio Technology Co., Ltd. (abbreviated “CapitalBio”) is the industrialization platform of the CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips. CapitalBio has always adhered to independent innovation and achievement transformation and has a complete industrial chain integrating R&D, production, sales, and thrid-party independent medical laboratory services; and responds to the national policy of “prevention first.” The health policy integrates modern medicine and traditional Chinese medicine to form a large health industry section that includes health products, health management, medical rehabilitation, and big data.